Literature DB >> 32492395

Low-Dose Sorafenib Acts as a Mitochondrial Uncoupler and Ameliorates Nonalcoholic Steatohepatitis.

Chongshu Jian, Jiajun Fu, Xu Cheng, Li-Jun Shen, Yan-Xiao Ji, Xiaoming Wang, Shan Pan, Han Tian, Song Tian, Rufang Liao, Kehan Song, Hai-Ping Wang, Xin Zhang, Yibin Wang, Zan Huang, Zhi-Gang She, Xiao-Jing Zhang, Lihua Zhu, Hongliang Li.   

Abstract

Entities:  

Year:  2020        PMID： 32492395      PMCID： PMC9377649          DOI： 10.1016/j.cmet.2020.05.006

Source DB:  PubMed          Journal:  Cell Metab        ISSN： 1550-4131            Impact factor:   31.373


× No keyword cloud information.
  3 in total

1.  A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging.

Authors:  Aki Morikawa; Milan Grkovski; Sujata Patil; Komal L Jhaveri; Kendrick Tang; John L Humm; Andrei Holodny; Kathryn Beal; Heiko Schöder; Andrew D Seidman
Journal:  Breast Cancer Res Treat       Date:  2021-06-10       Impact factor: 4.872

2.  Anthelmintics nitazoxanide protects against experimental hyperlipidemia and hepatic steatosis in hamsters and mice.

Authors:  Fengfeng Li; Man Jiang; Minghui Ma; Xuyang Chen; Yidan Zhang; Yixin Zhang; Yuanyuan Yu; Yunfeng Cui; Jiahui Chen; Hui Zhao; Zhijie Sun; Deli Dong
Journal:  Acta Pharm Sin B       Date:  2021-09-17       Impact factor: 14.903

3.  Mitochondria homeostasis: Biology and involvement in hepatic steatosis to NASH.

Authors:  Yu-Feng Li; Zhi-Fu Xie; Qian Song; Jing-Ya Li
Journal:  Acta Pharmacol Sin       Date:  2022-02-01       Impact factor: 7.169
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.